Human serum albumin
Human serum albumin (HSA) is the principal albumin-associated protein considered in the supplied biomedical literature.
Human serum albumin (HSA) is the principal albumin-associated protein considered in the supplied biomedical literature. Its capacity to bind diverse molecular partners gives it roles in drug complexation, pharmacokinetics, biodistribution, and the design of therapeutic and diagnostic systems. The cited studies examine HSA as a binding partner for small molecules, radiolabeled ligands, and engineered proteins; as a component of half-life-extension strategies; and as a biomaterial for hydrogel formation.
The recent work represents the broad Protein Applications theme rather than a single convergent biological question. Applications include cancer-targeting agents, cytotoxicity and tumor retention, albumin-mediated pharmacokinetic control, protein-derived hydrogels, and analytical measurement of serum albumin. Related systems involve binding to teicoplanin, mitoxantrone, gallium-labeled fibroblast activation protein inhibitors, and radiolabeled ligands directed against PSMA and GRPR, as well as fusion to coagulation factor IX and association with engineered single-domain proteins.
Where the papers sit
10 papers from the last 6 months study human serum albumin directly · updated from PubMed 5 Oct 2026
Study type 1 clinical trial · 4 human data · 5 preclinical
Themes 3 themes · 1 new direction
-
Albumin Binding for Drug Delivery
Albumin binding is being engineered to extend circulation while preserving tumor targeting and drug activity. Structural stability and affinity recur as determinants of pharmacokinetics for FAP inhibitors, PSMA/GRPR radioligands, and single-domain ADAPT proteins. Molecular anchoring of mitoxantrone and dual-surfaced designs aim to improve antitumor efficacy and safety. The remaining question is whether stronger binding consistently improves exposure without impairing release or target access.
6 papers · 60%
-
Therapeutic Protein Half-Life
Therapeutic protein half-life is the shared problem, spanning albumin adjunct therapy during endovascular reperfusion and extended-half-life clotting factors for gene therapy. Stroke work is testing whether albumin improves 90-day outcomes after ischemic large-vessel occlusion. Clotting-factor work instead seeks longer persistence to increase gene-transfer efficacy. The cluster links duration of exposure to efficacy, without a single clinical direction.
2 papers · 20%
-
Protein-Based Hydrogel Drug Delivery
Protein-derived hydrogels are being tuned from bulk rheology toward predictable tissue-level drug transport. Protein addition changes silica-hydrogel microstructure, while ion valency controls network architecture and delivery through tissue. The shared aim is to link composition and mesh structure to release and penetration rather than treat the gel as an inert carrier. Evidence remains materials-focused, with no established therapeutic winner or clinical endpoint.
2 papers · 20%
Human serum albumin becomes a target analyte for airborne-bioaerosol detection
The centrifugal microfluidic assay for airborne bioaerosols 42312931Jun departs from the set’s roles for albumin as a therapeutic adjunct, carrier, binding partner, pharmacokinetic anchor, or hydrogel component by using HSA itself as the analyte to be quantified in a fieldable sandwich ELISA. This shifts albumin from an intervention or material into a measurement target for point-of-exposure bioaerosol analysis.
Papers
The 10 papers from the last 6 months that study human serum albumin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Albumin Binding for Drug Delivery (6)
- Integrating Tumor Targeting and Half-Life Extension into a Dual-Surfaced Single-Domain ADAPT Protein. Molecular pharmaceutics · 7 Sept 2026 PMID 42704121
- Complexation of teicoplanin and sulfobutylether-β-cyclodextrin: experimental and theoretical insights into the potential relevance of their molecular interaction to teicoplanin pharmacokinetics. International journal of pharmaceutics · 18 Jul 2026 PMID 42471168
- Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular pharmaceutics · 14 Jul 2026 PMID 42447187
- Centrifugal microfluidics for rapid target analyte quantification in airborne bioaerosols. Lab on a chip · 18 Jun 2026 PMID 42312931
- Structural stability of human serum albumin complexes governs the blood circulation of gallium-Labeled FAP inhibitors. Bioorganic chemistry · 22 May 2026 PMID 42172798
- A molecular anchor for mitoxantrone: improving binding affinity to albumin for enhanced antitumor efficacy and safety. Journal of colloid and interface science · 23 Apr 2026 PMID 42025033
Therapeutic Protein Half-Life (2)
- Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial. European stroke journal · 5 Oct 2026 PMID 42831671
- Increased gene therapy efficacy through the use of extended half-life clotting factors. Blood advances · 2 Jul 2026 PMID 42392182
Protein-Based Hydrogel Drug Delivery (2)
- Impact of a protein addition on the microstructure and rheological properties of silica hydrogels. Soft matter · 1 Sept 2026 PMID 42676005
- Ion valency-driven control of network architecture and tissue-level drug transport in protein-derived hydrogels. International journal of biological macromolecules · 18 Jun 2026 PMID 42314886
By study type
Clinical trials (1)
- Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial. European stroke journal · 5 Oct 2026 PMID 42831671
Human data, design not indexed (4)
- Complexation of teicoplanin and sulfobutylether-β-cyclodextrin: experimental and theoretical insights into the potential relevance of their molecular interaction to teicoplanin pharmacokinetics. International journal of pharmaceutics · 18 Jul 2026 PMID 42471168
- Ion valency-driven control of network architecture and tissue-level drug transport in protein-derived hydrogels. International journal of biological macromolecules · 18 Jun 2026 PMID 42314886
- Centrifugal microfluidics for rapid target analyte quantification in airborne bioaerosols. Lab on a chip · 18 Jun 2026 PMID 42312931
- Structural stability of human serum albumin complexes governs the blood circulation of gallium-Labeled FAP inhibitors. Bioorganic chemistry · 22 May 2026 PMID 42172798
Preclinical: animal, cell and lab studies (5)
- Integrating Tumor Targeting and Half-Life Extension into a Dual-Surfaced Single-Domain ADAPT Protein. Molecular pharmaceutics · 7 Sept 2026 PMID 42704121
- Impact of a protein addition on the microstructure and rheological properties of silica hydrogels. Soft matter · 1 Sept 2026 PMID 42676005
- Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular pharmaceutics · 14 Jul 2026 PMID 42447187
- Increased gene therapy efficacy through the use of extended half-life clotting factors. Blood advances · 2 Jul 2026 PMID 42392182
- A molecular anchor for mitoxantrone: improving binding affinity to albumin for enhanced antitumor efficacy and safety. Journal of colloid and interface science · 23 Apr 2026 PMID 42025033
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-09-21. Drafted by language models from published abstracts; not medical advice.